The fourth Riyadh Global Medical Biotechnology Summit closed with more than 40 agreements and initiatives worth over SAR 5 billion (US$1.33 billion), a thirteenfold jump from the 2024 edition. With 15,000 visitors from 57 countries, highlights include a vaccine plant 85% complete that will localize up to 80% of Saudi Arabia's essential vaccine needs, a genomics Center of Excellence with Thermo Fisher, and clinical-trial partnerships with Novo Nordisk.